Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells-identification of a novel androgen response element

Nucleic Acids Research

Volumn 38, Issue 16, 2010, Pages 5351-5365

  Lanzino, Marilena ^a   Sisci, Diego ^a   Morelli, Catia ^a   Garofalo, Cecilia ^a   Catalano, Stefania ^a   Casaburi, Ivan ^a   Capparelli, Claudia ^a   Giordano, Cinzia ^a   Giordano, Francesca ^a   Maggiolini, Marcello ^a   Andò, Sebastiano ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CYCLIN D1; HISTONE DEACETYLASE 1; MESSENGER RNA; MULTIPROTEIN COMPLEX; NUCLEAR RECEPTOR DAX 1; ANDROSTANOLONE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL STRAIN MCF 7; CONTROLLED STUDY; GENE ACTIVITY; GENE CONTROL; GENE LOCATION; GENE REPRESSION; HORMONE ACTION; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION SITE; BINDING SITE; BREAST TUMOR; CELL LINE; CELL PROLIFERATION; DNA RESPONSIVE ELEMENT; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TUMOR CELL LINE;

ANDROGENS; BINDING SITES; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DAX-1 ORPHAN NUCLEAR RECEPTOR; DIHYDROTESTOSTERONE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROMOTER REGIONS, GENETIC; RECEPTORS, ANDROGEN; RESPONSE ELEMENTS;

EID: 77956504679     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkq278     Document Type: Article

References (78)

1. Arnold,A. and Papanikolaou,A. (2005) Cyclin D1 in breast cancer pathogenesis. J. Clin. Oncol., 23, 4215-4224.
2. Ormandy,C.J., Musgrove,E.A., Hui,R., Daly,R.J. and Sutherland,R.L. (2003) Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res. Treat., 78, 323-335.
3. Gillett,C., Fantl,V., Smith,R., Fisher,C., Bartek,J., Dickson,C., Barnes,D. and Peters,G. (1994) Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res., 54, 1812-1817.
4. Buckley,M.F., Sweeney,K.J., Hamilton,J.A., Sini,R.L., Manning,D.L., Nicholson,R.I., deFazio,A., Watts,C.K., Musgrove,E.A. and Sutherland,R.L. (1993) Expression and amplification of cyclin genes in human breast cancer. Oncogene, 8, 2127-2133.
5. Hodges,L.C., Cook,J.D., Lobenhofer,E.K., Li,L., Bennett,L., Bushel,P.R., Aldaz,C.M., Afshari,C.A. and Walker,C.L. (2003) Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol. Cancer Res., 1, 300-311.
6. Hui,R., Finney,G.L., Carroll,J.S., Lee,C.S., Musgrove,E.A. and Sutherland,R.L. (2002) Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res., 62, 6916-6923.
7. Jirstrom,K., Stendahl,M., Ryden,L., Kronblad,A., Bendahl,P.O., Stal,O. and Landberg,G. (2005) Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res., 65, 8009-8016.
8. Stendahl,M., Kronblad,A., Ryden,L., Emdin,S., Bengtsson,N.O. and Landberg,G. (2004) Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br. J. Cancer, 90, 1942-1948.
9. Wang,T.C., Cardiff,R.D., Zukerberg,L., Lees,E., Arnold,A. and Schmidt,E.V. (1994) Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature, 369, 669-671.
10. Lee,R.J., Albanese,C., Fu,M., D'Amico,M., Lin,B., Watanabe,G., Haines,G.K. 3rd, Siegel,P.M., Hung,M.C., Yarden,Y. et al. (2000) Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol. Cell. Biol., 20, 672-683.
11. Yu,Q., Geng,Y. and Sicinski,P. (2001) Specific protection against breast cancers by cyclin D1 ablation. Nature, 411, 1017-1021.
12. Grillo,M., Bott,M.J., Khandke,N., McGinnis,J.P., Miranda,M., Meyyappan,M., Rosfjord,E.C. and Rabindran,S.K. (2006) Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Res. Treat., 95, 185-194.
13. Dupont,J., Karas,M. and LeRoith,D. (2000) The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components. J. Biol. Chem., 275, 35893-35901.
14. Liu,M.M., Albanese,C., Anderson,C.M., Hilty,K., Webb,P., Uht,R.M., Price,R.H. Jr, Pestell,R.G. and Kushner,P.J. (2002) Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J. Biol. Chem., 277, 24353-24360.
15. Musgrove,E.A., Hamilton,J.A., Lee,C.S., Sweeney,K.J., Watts,C.K. and Sutherland,R.L. (1993) Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol. Cell. Biol., 13, 3577-3587.
16. Altucci,L., Addeo,R., Cicatiello,L., Dauvois,S., Parker,M.G., Truss,M., Beato,M., Sica,V., Bresciani,F. and Weisz,A. (1996) 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene, 12, 2315-2324.
17. Eeckhoute,J., Carroll,J.S., Geistlinger,T.R., Torres-Arzayus,M.I. and Brown,M. (2006) A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev., 20, 2513-2526.
18. Birrell,S.N., Hall,R.E. and Tilley,W.D. (1998) Role of the androgen receptor in human breast cancer. J Mammary Gland Biol. Neoplasia, 3, 95-103.
19. Somboonporn,W. and Davis,S.R. (2004) Testosterone effects on the breast: implications for testosterone therapy for women. Endocr. Rev., 25, 374-388.
20. Labrie,F., Luu-The,V., Labrie,C., Belanger,A., Simard,J., Lin,S.X. and Pelletier,G. (2003) Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr. Rev., 24, 152-182.
21. Yeh,S., Hu,Y.C., Wang,P.H., Xie,C., Xu,Q., Tsai,M.Y., Dong,Z., Wang,R.S., Lee,T.H. and Chang,C. (2003) Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor. J. Exp. Med., 198, 1899-1908.
22. Tworoger,S.S., Missmer,S.A., Barbieri,R.L., Willett,W.C., Colditz,G.A. and Hankinson,S.E. (2005) Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones. J. Natl Cancer Inst., 97, 595-602.
23. Missmer,S.A., Eliassen,A.H., Barbieri,R.L. and Hankinson,S.E. (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J. Natl Cancer Inst., 96, 1856-1865.
24. Dimitrakakis,C., Zhou,J., Wang,J., Belanger,A., LaBrie,F., Cheng,C., Powell,D. and Bondy,C. (2003) A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause, 10, 292-298.
25. Murphy,L.C. and Watson,P. (2002) Steroid receptors in human breast tumorigenesis and breast cancer progression. Biomed. Pharmacother., 56, 65-77.
26. Zhou,J., Ng,S., Adesanya-Famuiya,O., Anderson,K. and Bondy,C.A. (2000) Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J., 14, 1725-1730.
27. Lanzino,M., De Amicis,F., McPhaul,M.J., Marsico,S., Panno,M.L. and Ando,S. (2005) Endogenous coactivator ARA70 interacts with estrogen receptor alpha (ERalpha) and modulates the functional ERalpha/androgen receptor interplay in MCF-7 cells. J. Biol. Chem., 280, 20421-20430.
28. Ando,S., De Amicis,F., Rago,V., Carpino,A., Maggiolini,M., Panno,M.L. and Lanzino,M. (2002) Breast cancer: from estrogen to androgen receptor. Mol. Cell. Endocrinol., 193, 121-128.
29. de Launoit,Y., Dauvois,S., Dufour,M., Simard,J. and Labrie,F. (1991) Inhibition of cell cycle kinetics and proliferation by the androgen 5 alpha-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11-[16′ alpha-chloro-3′,17 beta-dihydroxy-estra-1′,3′,5′-(10′)triene-7′ alpha-yl] undecanamide in human breast cancer ZR-75-1 cells. Cancer Res., 51, 2797-2802.
30. Greeve,M.A., Allan,R.K., Harvey,J.M. and Bentel,J.M. (2004) Inhibition of MCF-7 breast cancer cell proliferation by 5alpha-dihydrotestosterone; a role for p21(Cip1/Waf1). J. Mol. Endocrinol., 32, 793-810.
31. Lanzino,M., Garofalo,C., Morelli,C., Le Pera,M., Casaburi,I., McPhaul,M.J., Surmacz,E., Ando,S. and Sisci,D. (2009) Insulin receptor substrate 1 modulates the transcriptional activity and the stability of androgen receptor in breast cancer cells. Breast Cancer Res. Treat., 115, 297-306.
32. Lea,O.A., Kvinnsland,S. and Thorsen,T. (1989) Improved measurement of androgen receptors in human breast cancer. Cancer Res., 49, 7162-7167.
33. Moinfar,F., Okcu,M., Tsybrovskyy,O., Regitnig,P., Lax,S.F., Weybora,W., Ratschek,M., Tavassoli,F.A. and Denk,H. (2003) Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer, 98, 703-711.
34. Riva,C., Dainese,E., Caprara,G., Rocca,P.C., Massarelli,G., Tot,T., Capella,C. and Eusebi,V. (2005) Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma. Virchows Arch., 447, 695-700.
35. Agoff,S.N., Swanson,P.E., Linden,H., Hawes,S.E. and Lawton,T.J. (2003) Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am. J. Clin. Pathol., 120, 725-731.
36. Soreide,J.A., Lea,O.A., Varhaug,J.E., Skarstein,A. and Kvinnsland,S. (1992) Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur. J. Surg. Oncol., 18, 112-118.
37. Kimura,N., Mizokami,A., Oonuma,T., Sasano,H. and Nagura,H. (1993) Immunocytochemical localization of androgen receptor with polyclonal antibody in paraffin-embedded human tissues. J. Histochem. Cytochem., 41, 671-678.
38. Sauter,E.R., Lininger,J., Magklara,A., Hewett,J.E. and Diamandis,E.P. (2004) Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. Int. J. Cancer, 108, 588-591.
39. Sauter,E.R., Tichansky,D.S., Chervoneva,I. and Diamandis,E.P. (2002) Circulating testosterone and prostate-specific antigen in nipple aspirate fluid and tissue are associated with breast cancer. Environ. Health Perspect., 110, 241-246.
40. Schippinger,W., Regitnig,P., Dandachi,N., Wernecke,K.D., Bauernhofer,T., Samonigg,H. and Moinfar,F. (2006) Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Virchows Arch., 449, 24-30.
41. Rakha,E.A., El-Sayed,M.E., Green,A.R., Lee,A.H., Robertson,J.F. and Ellis,I.O. (2007) Prognostic markers in triple-negative breast cancer. Cancer, 109, 25-32.
42. Lobaccaro,J.M., Lumbroso,S., Belon,C., Galtier-Dereure,F., Bringer,J., Lesimple,T., Heron,J.F., Pujol,H. and Sultan,C. (1993) Male breast cancer and the androgen receptor gene. Nat. Genet., 5, 109-110.
43. Kollara,A., Kahn,H.J., Marks,A. and Brown,T.J. (2001) Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers. Breast Cancer Res. Treat., 67, 245-253.
44. Tormey,D.C., Lippman,M.E., Edwards,B.K. and Cassidy,J.G. (1983) Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann. Intern. Med., 98, 139-144.
45. Ingle,J.N., Twito,D.I., Schaid,D.J., Cullinan,S.A., Krook,J.E., Mailliard,J.A., Tschetter,L.K., Long,H.J., Gerstner,J.G., Windschitl,H.E. et al. (1991) Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer, 67, 886-891.
46. Macedo,L.F., Guo,Z., Tilghman,S.L., Sabnis,G.J., Qiu,Y. and Brodie,A. (2006) Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res., 66, 7775-7782.
47. Sasano,H., Suzuki,T., Miki,Y. and Moriya,T. (2008) Intracrinology of estrogens and androgens in breast carcinoma. J. Steroid Biochem. Mol. Biol., 108, 181-185.
48. Hanley,K., Wang,J., Bourne,P., Yang,Q., Gao,A.C., Lyman,G. and Tang,P. (2008) Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. Hum. Pathol., 39, 386-392.
49. Gonzalez-Angulo,A.M., Stemke-Hale,K., Palla,S.L., Carey,M., Agarwal,R., Meric-Berstam,F., Traina,T.A., Hudis,C., Hortobagyi,G.N., Gerald,W.L. et al. (2009) Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin. Cancer Res., 15, 2472-2478.
50. Mosmann,T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63.
51. Zoppi,S., Marcelli,M., Deslypere,J.P., Griffin,J.E., Wilson,J.D. and McPhaul,M.J. (1992) Amino acid substitutions in the DNA-binding domain of the human androgen receptor are a frequent cause of receptor-binding positive androgen resistance. Mol. Endocrinol., 6, 409-415.
52. Recchia,A.G., Musti,A.M., Lanzino,M., Panno,M.L., Turano,E., Zumpano,R., Belfiore,A., Ando,S. and Maggiolini,M. (2009) A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells. Int. J. Biochem. Cell Biol., 41, 603-614.
53. Morelli,C., Garofalo,C., Sisci,D., del Rincon,S., Cascio,S., Tu,X., Vecchione,A., Sauter,E.R., Miller,W.H. Jr and Surmacz,E. (2004) Nuclear insulin receptor substrate 1 interacts with estrogen receptor alpha at ERE promoters. Oncogene, 23, 7517-7526.
54. Catalano,S., Giordano,C., Rizza,P., Gu,G., Barone,I., Bonofiglio,D., Giordano,F., Malivindi,R., Gaccione,D., Lanzino,M. et al. (2009) Evidence that leptin through STAT and CREB signaling enhances cyclin D1 expression and promotes human endometrial cancer proliferation. J. Cell. Physiol., 218, 490-500.
55. Cascio,S., Bartella,V., Garofalo,C., Russo,A., Giordano,A. and Surmacz,E. (2007) Insulin-like growth factor 1 differentially regulates estrogen receptor-dependent transcription at estrogen response element and AP-1 sites in breast cancer cells. J. Biol. Chem., 282, 3498-3506.
56. Lanzino,M., Garofalo,C., Morelli,C., Le Pera,M., Casaburi,I., McPhaul,M.J., Surmacz,E., Ando,S. and Sisci,D. (2009) Insulin receptor substrate 1 modulates the transcriptional activity and the stability of androgen receptor in breast cancer cells. Breast Cancer Res. Treat, 115, 297-306.
57. Yeap,B.B., Krueger,R.G. and Leedman,P.J. (1999) Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells. Endocrinology, 140, 3282-3291.
58. Verrijdt,G., Haelens,A. and Claessens,F. (2003) Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression. Mol. Genet. Metab., 78, 175-185.
59. Castro-Rivera,E., Samudio,I. and Safe,S. (2001) Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J. Biol. Chem., 276, 30853-30861.
60. Holter,E., Kotaja,N., Makela,S., Strauss,L., Kietz,S., Janne,O.A., Gustafsson,J.A., Palvimo,J.J. and Treuter,E. (2002) Inhibition of androgen receptor (AR) function by the reproductive orphan nuclear receptor DAX-1. Mol. Endocrinol., 16, 515-528.
61. Agoulnik,I.U., Krause,W.C., Bingman,W.E. 3rd, Rahman,H.T., Amrikachi,M., Ayala,G.E. and Weigel,N.L. (2003) Repressors of androgen and progesterone receptor action. J. Biol. Chem., 278, 31136-31148.
62. Yuan,X., Lu,M.L., Li,T. and Balk,S.P. (2001) SRY interacts with and negatively regulates androgen receptor transcriptional activity. J. Biol. Chem., 276, 46647-46654.
63. Haberland,M., Montgomery,R.L. and Olson,E.N. (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet., 10, 32-42.
64. White,J.H., Fernandes,I., Mader,S. and Yang,X.J. (2004) Corepressor recruitment by agonist-bound nuclear receptors. Vitam. Horm., 68, 123-143.
65. Peters,A.A., Buchanan,G., Ricciardelli,C., Bianco-Miotto,T., Centenera,M.M., Harris,J.M., Jindal,S., Segara,D., Jia,L., Moore,N.L. et al. (2009) Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res., 69, 6131-6140.
66. Ogawa,Y., Hai,E., Matsumoto,K., Ikeda,K., Tokunaga,S., Nagahara,H., Sakurai,K., Inoue,T. and Nishiguchi,Y. (2008) Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int. J. Clin. Oncol., 13, 431-435.
67. Liu,Y.N., Liu,Y., Lee,H.J., Hsu,Y.H. and Chen,J.H. (2008) Activated androgen receptor downregulates E-cadherin gene expression and promotes tumor metastasis. Mol. Cell. Biol., 28, 7096-7108.
68. Cicatiello,L., Addeo,R., Sasso,A., Altucci,L., Petrizzi,V.B., Borgo,R., Cancemi,M., Caporali,S., Caristi,S., Scafoglio,C. et al. (2004) Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol. Cell. Biol., 24, 7260-7274.
69. Sabbah,M., Courilleau,D., Mester,J. and Redeuilh,G. (1999) Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc. Natl Acad. Sci. USA, 96, 11217-11222.
70. Herber,B., Truss,M., Beato,M. and Muller,R. (1994) Inducible regulatory elements in the human cyclin D1 promoter. Oncogene, 9, 2105-2107.
71. Moehren,U., Denayer,S., Podvinec,M., Verrijdt,G. and Claessens,F. (2008) Identification of androgen-selective androgen-response elements in the human aquaporin-5 and Rad9 genes. Biochem. J., 411, 679-686.
72. Haelens,A., Verrijdt,G., Callewaert,L., Christiaens,V., Schauwaers,K., Peeters,B., Rombauts,W. and Claessens,F. (2003) DNA recognition by the androgen receptor: evidence for an alternative DNA-dependent dimerization, and an active role of sequences flanking the response element on transactivation. Biochem. J., 369, 141-151.
73. McEwan,I.J. (2004) Molecular mechanisms of androgen receptor-mediated gene regulation: structure-function analysis of the AF-1 domain. Endocr. Relat. Cancer, 11, 281-293.
74. Giguere,V. (1999) Orphan nuclear receptors: from gene to function. Endocr. Rev., 20, 689-725.
75. Lalli,E. and Sassone-Corsi,P. (2003) DAX-1, an unusual orphan receptor at the crossroads of steroidogenic function and sexual differentiation. Mol. Endocrinol., 17, 1445-1453.
76. Zhang,H., Thomsen,J.S., Johansson,L., Gustafsson,J.A. and Treuter,E. (2000) DAX-1 functions as an LXXLL-containing corepressor for activated estrogen receptors. J. Biol. Chem., 275, 39855-39859.
77. Conde,I., Alfaro,J.M., Fraile,B., Ruiz,A., Paniagua,R. and Arenas,M.I. (2004) DAX-1 expression in human breast cancer: comparison with estrogen receptors ER-alpha, ER-beta and androgen receptor status. Breast Cancer Res., 6, R140-R148.
78. Suzuki,T., Miki,Y., Moriya,T., Akahira,J., Ishida,T., Hirakawa,H., Yamaguchi,Y., Hayashi,S. and Sasano,H. (2007) 5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. Int. J. Cancer, 120, 285-291.